Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Analyst Ratings
Moderate Buy
9 Buy
6 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARVN Stock 12 Month Forecast
Average Price Target
$20.62
▲(63.91% Upside)
| Highest Price Target$110.00 | Average Price Target$20.62 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$16
Buy
27.19%
Upside
Reiterated
12/08/25
Stephens
$14→$15
Buy
19.24%
Upside
Reiterated
11/10/25
H.C. Wainwright
$18
Buy
43.08%
Upside
Reiterated
11/06/25
Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding CompanyValuations and Risks. Our price target of $18 is based on an equally-weighted composite of: (a) $18.6/share, as a 25x multiple of taxed and diluted $1.33 discounted back to and (b) an NPV of $18/ share (discounted cash flow analysis using an 14.0% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks.
Barclays
$15→$16
Buy
27.19%
Upside
Reiterated
11/06/25
Citi
$10
Hold
-20.51%
Downside
Reiterated
11/06/25
Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold RatingWe like the opportunity in Parkinson’s disease (PD) with ARV-102, the company’s investigational PROTAC targeting LRRK2 – see to Model. We expect Ph1 multiple dose cohort data (primarily biomarker-related) in PD patients early next year to unveil how much LRRK2 degradation/pathway engagement occurs in PD patients treated with ARV-102 relative to what’s been seen already in healthy volunteers (whose baseline LRRK2 levels in CSF are ~2-3x lower than those of PD patients). Clarity on potential translation to clinical benefits should come later when ARVN can dose beyond 28 days of treatment (chronic tox study is underway). ARVN also plans to initiate a Ph1b in patients with progressive supranuclear palsy (PSP) in 1H26 (can potentially start a registration-quality Ph2 before Ph1b is complete).
TD Cowen
―
Hold
―
Reiterated
11/05/25
Oppenheimer
―
Hold
―
Reiterated
11/05/25
Bank of America Securities
$12
Hold
-4.61%
Downside
Reiterated
11/05/25
BTIG
$10→$14
Buy
11.29%
Upside
Reiterated
11/03/25
Goldman Sachs
$8→$6
Sell
-52.31%
Downside
Downgraded
10/16/25
Morgan Stanley
$10
Hold
-20.51%
Downside
Reiterated
09/22/25
Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD LandscapeWe view the Vepdeg out-licensing strategy as a positive, as it reduces the need for significant investment in building a sales force and sharing 50% of commercialization costs, particularly given the smaller market opportunity now anticipated for vepdeg (see our takeaways HERE). That said, we await evidence of partnering interest given the competitive landscape in the SERD space. ARVN’s focus now shifts to its early-stage pipeline, with upcoming catalysts including Ph1 data for ARV-102 (LRRK2 degrader) in Parkinson’s disease by YE25/1H26 and Ph1 data for its ARV-393 (BCL6 degrader) by YE25.
Wells Fargo
$16
Buy
27.19%
Upside
Reiterated
09/19/25
Wedbush
$10→$9
Hold
-28.46%
Downside
Reiterated
09/18/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/18/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$16
Buy
27.19%
Upside
Reiterated
12/08/25
Stephens
$14→$15
Buy
19.24%
Upside
Reiterated
11/10/25
H.C. Wainwright
$18
Buy
43.08%
Upside
Reiterated
11/06/25
Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding CompanyValuations and Risks. Our price target of $18 is based on an equally-weighted composite of: (a) $18.6/share, as a 25x multiple of taxed and diluted $1.33 discounted back to and (b) an NPV of $18/ share (discounted cash flow analysis using an 14.0% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks.
Barclays
$15→$16
Buy
27.19%
Upside
Reiterated
11/06/25
Citi
$10
Hold
-20.51%
Downside
Reiterated
11/06/25
Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold RatingWe like the opportunity in Parkinson’s disease (PD) with ARV-102, the company’s investigational PROTAC targeting LRRK2 – see to Model. We expect Ph1 multiple dose cohort data (primarily biomarker-related) in PD patients early next year to unveil how much LRRK2 degradation/pathway engagement occurs in PD patients treated with ARV-102 relative to what’s been seen already in healthy volunteers (whose baseline LRRK2 levels in CSF are ~2-3x lower than those of PD patients). Clarity on potential translation to clinical benefits should come later when ARVN can dose beyond 28 days of treatment (chronic tox study is underway). ARVN also plans to initiate a Ph1b in patients with progressive supranuclear palsy (PSP) in 1H26 (can potentially start a registration-quality Ph2 before Ph1b is complete).
TD Cowen
―
Hold
―
Reiterated
11/05/25
Oppenheimer
―
Hold
―
Reiterated
11/05/25
Bank of America Securities
$12
Hold
-4.61%
Downside
Reiterated
11/05/25
BTIG
$10→$14
Buy
11.29%
Upside
Reiterated
11/03/25
Goldman Sachs
$8→$6
Sell
-52.31%
Downside
Downgraded
10/16/25
Morgan Stanley
$10
Hold
-20.51%
Downside
Reiterated
09/22/25
Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD LandscapeWe view the Vepdeg out-licensing strategy as a positive, as it reduces the need for significant investment in building a sales force and sharing 50% of commercialization costs, particularly given the smaller market opportunity now anticipated for vepdeg (see our takeaways HERE). That said, we await evidence of partnering interest given the competitive landscape in the SERD space. ARVN’s focus now shifts to its early-stage pipeline, with upcoming catalysts including Ph1 data for ARV-102 (LRRK2 degrader) in Parkinson’s disease by YE25/1H26 and Ph1 data for its ARV-393 (BCL6 degrader) by YE25.
Wells Fargo
$16
Buy
27.19%
Upside
Reiterated
09/19/25
Wedbush
$10→$9
Hold
-28.46%
Downside
Reiterated
09/18/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/18/25
Best Analysts Covering Arvinas Holding Company
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+2.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.54% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+3.33%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +3.33% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+42.03%
reiterated a buy rating last month
Copying Jeet Mukherjee's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +42.03% per trade.
2 Years
xxx
Success Rate
7/9 ratings generated profit
Average Return
+42.03%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +42.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARVN Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
13
15
18
13
5
Buy
0
2
3
5
4
Hold
25
21
22
21
15
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
38
38
44
40
25
Each month's total comprises the sum of three months' worth of ratings.
ARVN Financial Forecast
ARVN Stock Forecast FAQ
What is ARVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Arvinas Holding Company’s 12-month average price target is 20.62.
What is ARVN’s upside potential, based on the analysts’ average price target?
Arvinas Holding Company has 63.91% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARVN a Buy, Sell or Hold?
Arvinas Holding Company has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 1 sell ratings.
What is Arvinas Holding Company’s price target?
The average price target for Arvinas Holding Company is 20.62. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $6.00. The average price target represents 63.91% Increase from the current price of $12.58.
The highest analyst price target is $110.00 ,the lowest forecast is $6.00. The average price target represents 63.91% Increase from the current price of $12.58.
What do analysts say about Arvinas Holding Company?
Arvinas Holding Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of ARVN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.